Syros Pharmaceuticals, Inc. (SYRS) Key Metrics
SYRS valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $10,732
- Enterprise value
- $2.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.0
- Price / book
- 10.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.69
SYRS key metrics, 2014–2023
Fiscal year ended December 31, 2023 · U.S. dollarsSYRS returns How much profit the business earns on the capital it uses.
SYRS per-share figures Results divided by the shares outstanding at year-end.
SYRS financial health Debt, liquidity and how easily interest is covered.
SYRS efficiency & capital use Working capital cycle and where the cash goes.
SYRS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SYRS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SYRS cash returned to shareholders
SYRS key metrics
2014–2023| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Per share | ||||||||||
| Revenue per share | $0.35 | $1.18 | $3.76 | — | — | — | — | — | — | — |
| Earnings per share | −$5.81 | −$7.49 | −$13.84 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$3.87 | −$9.74 | −$15.92 | — | — | — | — | — | — | — |
| Free cash flow per share | −$3.88 | −$9.84 | −$16.12 | — | — | — | — | — | — | — |
| Cash per share | $4.93 | $16.02 | $20.85 | — | — | — | — | — | — | — |
| Book value per share | $0.59 | $10.11 | $13.63 | — | — | — | — | — | — | — |
| Tangible book value per share | $0.59 | $10.11 | $13.63 | — | — | — | — | — | — | — |
| Dividends per share | $1.49 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.10 | $0.20 | — | — | — | — | — | — | — |
| Debt per share | $2.19 | $5.03 | $10.42 | — | — | — | — | — | — | — |
| Shares outstanding | 28.3M | 12.6M | 6.3M | — | — | — | — | — | — | — |
| Change in shares outstanding | +124.2% | +102.0% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −227.9% | −88.9% | −98.5% | −99.0% | −95.6% | −86.6% | −74.0% | −83.3% | −63.2% | −41.8% |
| Return on assets (ROA) | −79.8% | −44.3% | −43.7% | −46.3% | −58.8% | −67.2% | −63.6% | −70.8% | −56.7% | −40.4% |
| Return on tangible assets | −97.9% | −38.7% | −47.3% | −39.4% | −50.3% | −58.3% | −68.8% | −52.3% | −68.3% | −21.8% |
| Free cash flow margin | — | −835.4% | −429.1% | −402.2% | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $62.1M | $63.6M | $65.2M | $66.2M | $25.9M | $31,000 | $53,000 | $221,000 | $339,000 | $339,000 |
| Cash & short-term investments | $139.5M | $202.3M | $130.4M | $174.0M | $91.4M | $99.7M | $72.0M | $83.6M | $35.9M | $60.4M |
| Net debt | −$77.5M | −$138.7M | −$65.2M | −$107.8M | −$65.5M | −$99.6M | −$72.0M | −$83.4M | −$35.6M | −$60.1M |
| Debt / equity | 3.73 | 0.50 | 0.76 | 0.73 | 0.33 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt / assets | 0.37 | 0.26 | 0.36 | 0.31 | 0.17 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Current ratio | 3.95 | 6.87 | 4.33 | 6.24 | 4.87 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Quick ratio | 3.95 | 6.87 | 4.33 | 6.24 | 4.86 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Interest coverage | -25.2 | -32.9 | -25.4 | -45.9 | — | — | — | — | — | — |
| Working capital | $108.3M | $180.6M | $105.1M | $149.9M | $91.0M | $82.2M | $60.7M | $75.9M | $28.5M | $59.3M |
| Invested capital | −$60.8M | −$11.0M | $20.0M | −$17.2M | $13.7M | −$21.1M | −$6.7M | −$2.8M | −$1.5M | $187,000 |
| Tangible asset value | $16.7M | $127.7M | $85.2M | $90.6M | $79.2M | $78.6M | $65.3M | $80.6M | $34.0M | $60.2M |
| Net current asset value | −$6.5M | $94.6M | $38.9M | $55.9M | $43.7M | $73.6M | $60.0M | $74.8M | $26.9M | $59.3M |
| Graham net-net per share | −$0.42 | $6.87 | $5.58 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $42.1M | — | — | $433,000 | $161,000 | — | $0 | $0 | — | — |
| Share buybacks (net) | $0 | $81,000 | $0 | $0 | $0 | $0 | $0 | $0 | $620,000 | $0 |
| Capex / revenue | 2.7% | 8.3% | 5.3% | 22.1% | 637.6% | 67.5% | 74.6% | 732.5% | 371.0% | — |
| Capex / depreciation | 0.12 | 0.42 | 0.41 | 1.10 | 4.64 | 0.86 | 0.54 | 1.82 | 1.95 | 0.78 |
| Stock-based compensation / revenue | 105.0% | 76.7% | 44.1% | 72.5% | 496.4% | 322.4% | 401.4% | 1,335.6% | 1,019.9% | — |
| R&D / revenue | 1,088.5% | 752.3% | 425.2% | 504.0% | 2,938.7% | 2,447.9% | 3,805.3% | 11,929.7% | 7,699.7% | — |
| SG&A / revenue | 284.6% | 196.9% | 98.1% | 141.3% | 1,083.7% | 788.5% | 1,261.7% | 3,300.6% | 1,807.3% | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | 57.3 | 41.3 | 271.9 | 3,712.2 | — | — | 998.3 | — | — |
| Days of inventory on hand | — | 0.0 | — | — | — | — | — | 0.0 | — | — |
| Days payables outstanding | 1,455.1 | 621.4 | — | — | — | — | 15.8 | 28.9 | 1,807.7 | — |
| Cash conversion cycle (days) | — | -564.1 | — | — | — | — | — | 969.4 | — | — |
| Receivables turnover | — | 6.37 | 8.85 | 1.34 | 0.10 | — | — | 0.37 | — | 0.00 |
| Payables turnover | 0.25 | 0.59 | 0.00 | 0.00 | 0.00 | 0.00 | 23.10 | 12.62 | 0.20 | 0.00 |
| Inventory turnover | — | 2,967,000.00 | — | 0.00 | 0.00 | — | — | 47,007,000.00 | — | — |
| Asset turnover | 0.05 | 0.07 | 0.12 | 0.08 | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 |
| Average receivables | — | $2.3M | $2.7M | $11.2M | $20.2M | — | — | $867,000 | — | $867,000 |
| Average payables | $9.0M | $5.1M | $3.6M | $4.7M | $4.6M | $2.8M | $2.3M | $3.7M | $3.0M | $761,000 |
| Average inventory | — | $1 | — | $145,000 | $290,000 | — | $0 | $1 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SYRS's annual financial statements (latest annual report filed March 27, 2024) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SYRS valuation and financial ratios
Syros Pharmaceuticals earned a return on equity of −227.9% in fiscal 2023. It ended the year with $62.1 million of debt and $139.5 million in cash and short-term investments, a net cash position of $77.5 million. It returned $42.1 million to shareholders: $42.1 million in dividends and $0 in share buybacks.
See the SYRS income statement, the SYRS chart for price history, or the SYRS stock overview for the latest quote and news.
SYRS key metrics FAQ
What is Syros Pharmaceuticals's return on equity?
Syros Pharmaceuticals's return on equity (ROE) was −227.9% in fiscal 2023: net income of -$164.6 million on average shareholders' equity of $72.2 million.
How much debt does Syros Pharmaceuticals have?
Syros Pharmaceuticals had total debt of $62.1 million at the end of fiscal 2023, a debt-to-equity ratio of 3.73 and more cash than debt.
What is Syros Pharmaceuticals's current ratio?
Syros Pharmaceuticals's current ratio was 3.95 at the end of fiscal 2023: current assets were 3.95 times current liabilities.